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Abstract
ATP-binding cassette (ABC) transporters have often been refractory to over-expression. Using the C41(DE3) E. coli as a host strain,
membrane vesicles highly enriched (>50%) in YvcC, a previously uncharacterized ABC transporter from Bacillus subtilis homologous to P-
glycoprotein multidrug transporters, were obtained. The functionality of YvcC was assessed by its high vanadate-sensitive ATPase activity
and its ability to transport a fluorescent drug, the Hoechst 33342.
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1. Introduction
ATP-binding cassette (ABC) transporters constitute a
huge family of proteins which are involved in the import
or export of a wide diversity of substrates in all living
organisms [1]. In bacteria, their utmost implication in many
cellular processes stems from the fact that they often
constitute the largest protein family [2–4]. Thus, these
transporters are involved in the uptake of essential nutrients,
the secretion of either virulence factors, proteases or toxins,
the export of drugs like noxious compounds, and in anti-
biotic resistances developed by pathogenic bacteria [5,6]. In
human, many diseases are associated with either a dysfunc-
tion of an ABC transporter, for instance the CFTR channel
in cystic fibrosis, or the over-expression of others such as P-
glycoprotein or ‘‘Multidrug Resistance associated Protein’’
(MRP), thereby allowing cancer cells to escape therapeutic
treatments by conferring a multidrug resistance (MDR)
phenotype [7]. ABC transporters are constituted of at least
four building blocks: two membrane-spanning domains
involved in substrate translocation, and two nucleotide-
binding domains energizing the transporter. The latter
domains are the most conserved in sequence, and notably
contain the signature of this family [8,9]. These four
domains are found either as separate subunits (for instance,
in the maltose transporter), or fused together to form three,
two (designated as half-transporters) or even one single
polypeptide (most eukaryotic transporters fall in the latter
category). Importers, which are found only in bacteria, have
an additional subunit involved in the extracellular capture of
the substrate [1].
Despite many efforts, functional and structural character-
ization of membrane proteins have often been hampered by
the lack of efficient over-producing systems [10]. Hence,
although E. coli is usually an organism of choice for the
over-expression of proteins, difficulties have been encoun-
tered when trying to over-produce bacterial membrane
proteins such as ABC transporters. For instance, over-
expression of the bacterial full-length HlyB, involved in
haemolysin export, could not be obtained in E. coli [11].
Also, over-expression of LmrA, the first bacterial multidrug
transporter akin to human P-glycoprotein, was only
achieved by using a homologous Lactococcus lactis over-
expression system with a specific nisin-inducible promoter
[12]. Here, we show that the use of the C41(DE3) E. coli
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mutant strain [13] is particularly well-suited and efficient for
the over-production of YvcC, a multidrug-like ABC-trans-
porter from Bacillus subtilis. Membrane vesicles highly
enriched in YvcC are able to hydrolyze ATP in a vana-
date-sensitive manner and to actively transport a fluorescent
drug. Therefore, these results show that YvcC is correctly
folded in the membrane as a fully functional transporter. The
strategy described here might also be applicable to a broader
spectrum of membrane proteins, especially when scientists
face the challenging goal of purifying membrane proteins in
high yield for structural purposes.
2. Materials and methods
The E. coli C41(DE3) host strain, a mutant strain of
BL21(DE3), has been described previously [13]. The yvcC
gene was amplified by PCR using a DNA template prepared
from B. subtilis, and verification of the correct sequence was
made by DNA sequencing. The gene was then cloned into a
pET23b(+) vector (Novagen), allowing the addition of six
consecutive histidine residues on the carboxyl terminus of
the protein. For the over-expression, a freshly transformed
colony was inoculated into 2 YT broth medium (Bio 101
Inc.) and 0.7 mM isopropyl h-D-thiogalactopyranoside
(IPTG) was added when the OD600 nm reached 0.6. The
culture was further grown for 4 h at 25 jC and bacteria were
collected by a low-speed centrifugation (7500 g, 10 min)
at 4 jC; all subsequent steps were carried out at the same
temperature. Pellets were re-suspended in buffer A (50 mM
Tris–HCl pH 8.0, 5 mM MgCl2, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 5 AM leupeptine and 5 AM
pepstatine) containing 30 U/ml of benzonase, and bacteria
were lysed by two successive passages through a French
pressure cell (18000 psi). Ethylenediaminetetraacetic acid
(EDTA) was then added at 10 mM, and unbroken cells and
debris were removed by centrifugation for 30 min at
15000 g. Membrane vesicles were collected by centrifu-
gation at 100000 g for 60 min, re-suspended in buffer A
(except that MgCl2 was replaced by 1.5 mM EDTA) and
centrifuged again at the same speed. The membrane vesicles
were finally suspended in 20 mM Tris–HCl pH 8.0, 300
mM sucrose,1 mM EDTA and stored as small aliquots in
liquid nitrogen.
ATPase activity was measured by Pi release. Briefly,
control or YvcC-enriched membranes (2 Ag of proteins)
were incubated at 24 jC for 30 min in 50 mM Hepes/KOH
pH 8.0, 7 mM ATP, 7 mM MgCl2, 2 mM NaN3, and in the
presence of increasing concentrations of vanadate as indi-
cated in the figure legend (final volume of 50 Al). The
reactions were stopped by addition of 1 ml of 20 mM
H2SO4 and samples were immediately transferred on ice.
The Pi release was then measured by a colorimetric method
as previously described [14].
For Hoechst 33342 (2V-[4-ethoxyphenyl]-5-[4-methyl-1-
piperazinyl]-2,5V-bis-1H-benzimidazole; Sigma) transport
assay, variations in fluorescence intensity were monitored
with a Photon Technology International Quanta Master I
fluorimeter, using excitation and emission wavelengths of
355 and 457 nm, and slit widths of 2 and 4 nm, respectively.
Membrane vesicles (500 Ag of protein) were added into a 3
ml cuvette containing 2 ml of 50 mM Hepes/KOH pH 8.0, 2
mM MgCl2, 8.5 mM NaCl, 40 Ag pyruvate kinase
(E.C.2.7.1.40) and 4 mM phosphoenolpyruvate. After 1
min incubation at 25 jC, 2 AM Hoechst 33342 was added
(from a 1 mM stock solution in water), and its fluorescence
was recorded for 1–2 min. ATP was then added to a final
concentration of 2 mM and the fluorescence intensity was
monitored for several minutes.
3. Results and discussion
In order to identify an MDR-like ABC transporter in B.
subtilis, a computer search was initiated on its whole
genome using the Subtilist web server http://genolist.pas-
teur.fr/SubtiList/. Among all the open reading frames of B.
subtilis, a putative ABC transporter of unknown function,
called YvcC [2], showed the highest sequence homology to
LmrA (41.5% of identity) and also a high homology to each
half of human P-glycoprotein (28.8% and 27.7% of identity
with the N- and C-terminus halves, respectively). The yvcC
gene was cloned and the corresponding protein was suc-
cessfully over-expressed in the C41(DE3) E. coli strain (Fig.
1, left panel). This strain, which was derived from parental
BL21(DE3) strain due to an uncharacterized mutation, has
been shown to increase the yield of many over-expressed
proteins, notably membrane proteins [13]. A high expres-
sion level was also detected in the parental BL21(DE3)
strain but, and in contrast to C41(DE3), induction by IPTG
stopped the bacterial growth (Fig. 1, right panel). This
different behavior between the parental and the mutant
strains was previously observed when over-expression of
some toxic proteins was attempted [13]. Here, this led to an
overall lower yield in YvcC-containing BL21(DE3) cells as
compared to YvcC-containing C41(DE3) cells, a drawback
for a starting material when the goal is to purify a protein in
high yield. Moreover, and especially when using the
BL21(DE3) as a host strain, the yvcC gene-carrying plasmid
was rather unstable when IPTG was added to an exponen-
tially growing culture derived from an overnight grown pre-
culture (not shown). Over-expression of the MDR ABC
transporter LmrA, isolated from L. lactis, was likewise
obtained by using C41(DE3) (not shown here), showing
that this special strain might be useful as a host for the over-
expression of ABC transporters from various origins. In all
cases, the presence of the protein of interest was confirmed
by Western blotting using a monoclonal antibody directed
against the hexahistidine tag. Recently, over-expression of
the b-subunit of E. coli F0F1 ATP synthase in the C41(DE3)
strain was reported to occur through a high proliferation of
intracellular membranes [15]. While these intracellular
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membranes were pelleted by a low-speed centrifugation
[15], the YvcC-enriched membrane vesicles were collected
by a high-speed centrifugation suggesting that a different
scenario occurred here.
As shown in Fig. 2 (left panel), YvcC was by far the most
abundant protein in the membrane vesicles. A quantification
of YvcC in this fraction, by densitometry analysis of the
Coomassie brilliant blue-stained gel, allowed us to estimate
that YvcC amounted for about 50% of the whole membrane
proteins. To our knowledge, such a high yield of recovery in
the membrane fraction has never been achieved previously
for any MDR-like ABC transporter, neither of eukaryotic
origin [16–18], nor in the case of LmrA. The latter
amounted to about 30–35% of total membrane proteins
by using a nisin-inducible promoter specific for a homolo-
gous over-expression in L. lactis [12].
The functionality of over-produced YvcC was assessed
first by measuring its ATPase activity. YvcC-enriched
Fig. 1. Over-expression of YvcC in the mutant C41(DE3) or parental BL21(DE3) E. coli host strains. Left panel, Coomassie brilliant blue-stained SDS-PAGE
(12%) of C41(DE3) (lanes 2 and 3) or BL21(DE3) (lane 4) E. coli strains transformed with pET23b(+)/yvcC. Lane 2 was a sample withdrawn before IPTG
induction, and lanes 3 and 4 were samples obtained after IPTG induction. Lane 1 corresponded to the molecular weight markers. The position of YvcC is
indicated by an arrowhead. Right panel, growth of C41(DE3) (o) or BL21(DE3) (5) E. coli strains transformed with pET23b(+)/yvcC, after induction by IPTG
(added at time 0).
Fig. 2. Accumulation of YvcC in the membrane vesicles and its vanadate-sensitive ATPase activity. Left panel, Coomassie brilliant blue-stained SDS-PAGE
(12%) of membrane vesicles prepared from the C41(DE3) strain transformed with either the pET23b(+) (lane 2) or the pET23b(+)/yvcC (lane 3). Lane 1
corresponds to the molecular weight markers. The position of over-expressed YvcC is indicated by the arrowhead. Right panel, inhibition by vanadate of
ATPase activities of control or YvcC-containing vesicles. ATPase activities of control (o) or YvcC-containing vesicles (.) were measured by Pi release as
described in Materials and methods.
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vesicles exhibited a high ATPase activity of about 160 nmol/
min/mg of total proteins corresponding to an activity of
about 270 nmol/min/mg of YvcC. This activity and in
contrast to the much lower activity of control vesicle was
highly sensitive to vanadate inhibition (Fig. 2, right panel).
A concentration of about 10 AM vanadate produced an
inhibition of about 50% of YvcC ATPase activity, which is
similar to the value reported for the inhibition of P-glyco-
protein ATPase activity [19]. Furthermore, the ability of
YvcC to transport a fluorescent drug, the Hoechst 33342
previously shown to be transported by P-glycoprotein [20]
or LmrA [12], was investigated. Fig. 3 shows that, whereas
inside–out control vesicles were unable to transport the
Hoechst 33342, YvcC-enriched vesicles were quite efficient
to actively transport this drug upon ATP addition. This
transport was fully prevented by prior addition of vinblas-
tine, another substrate of P-glycoprotein [21] and LmrA
[22].
4. Conclusions
A high over-expression of an ABC transporter from B.
subtilis previously uncharacterized, YvcC, was achieved
here by using the C41(DE3) E. coli as a host strain, and
the membrane vesicles derived thereof were astonishingly
enriched in this transporter. This property allowed us to
show that YvcC bears, like its bacterial or eukaryotic
counterparts (LmrA or P-glycoprotein, respectively), the
ability to extrude the fluorescent dye Hoechst 33342. Thus,
YvcC is embedded in the membrane in a fully functional
conformation and, consequently, this membrane preparation
constitutes a suitable material for purification of YvcC in
high yield (Steinfels et al., manuscript in preparation). This
feature is a prerequisite for any biochemical studies, espe-
cially for structural purposes, and we have recently taken
advantage of this opportunity to determine the YvcC 3-D
structure at a resolution of about 25 A˚ [23].
Given the preponderance of the ABC transporter family,
especially in the bacterial world [24], the C41(DE3) strain
should be useful for the study of many ABC transporters yet
uncharacterized. Additionally, it might be suitable for the
over-expression of other bacterial MDR pumps, including
for instance those belonging to the Major Facilitator Super-
family [25]. Even beyond the MDR scope, over-expression
of any bacterial membrane protein is a challenging step and,
when successful, represents a major breakthrough towards
its characterization.
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